NDAORALTABLETPriority Review
Approved
Feb 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Data completeness
7/8 — Comprehensive
Priority Review
FILSPARI (sparsentan) by Travere Therapeutics is endothelin receptor antagonists [moa]. First approved in 2023.
Drug data last refreshed 34m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FILSPARI (sparsentan) is an oral endothelin receptor antagonist approved in February 2023 for the treatment of IgA nephropathy. It works by blocking endothelin receptors to reduce proteinuria and slow disease progression in patients with this rare kidney disorder.
$0.005BPart D
Peak10.9 years to LOEPeak-stage asset with early market penetration (~426 Part D claims in 2023) indicates aggressive commercial ramp-up phase requiring robust sales, reimbursement, and market development teams.
Mechanism of Action
Endothelin Receptor Antagonists
Pharmacologic Class:
Endothelin Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Started Jul 2026
20 enrolled
Proteinuric Renal DiseaseProteinuric Kidney DiseaseProteinuria+1 more
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
Started Oct 2025
20 enrolled
ProteinuriaImmunoglobulin A (IgA) NephropathyFocal Segmental Glomerulosclerosis+1 more
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Started May 2023
48 enrolled
Immunoglobulin A Nephropathy
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Started Aug 2021
67 enrolled
Focal Segmental GlomerulosclerosisMinimal Change DiseaseImmunoglobulin A Nephropathy+2 more
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
Started Dec 2020
24 enrolled
Immunoglobulin A NephropathyKidney DiseasesGlomerulonephritis, IGA+3 more
Worked on FILSPARI at Travere Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.